1832 Asset Management L.P. Exelixis, Inc. Transaction History

1832 Asset Management L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $5.19 Million - $6.19 Million	272,400 New	272,400 $5.95 Million
Q1 2020 May 14, 2020	SELL	$14.46 - $21.8 $1,446 - $2,180	-100 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $1,515 - $1,889	100 New	100 $2,000
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $41.4 Million - $59.6 Million	-1,869,100 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $43.6 Million - $54.7 Million	1,869,100	1,869,100 $43 Million

502

243M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $10.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of 1832 Asset Management L.P., based on Form 13F filings with the SEC.

Stay updated on 1832 Asset Management L.P. with notifications on news.